Czechia· CZ-0238468

PALYNZIQ

A pegvaliase product containing pegvaliase, registered in Czechia by BioMarin International Limited, Dublin. The same ATC class is registered in 10 of our 19 countries.

ATC A16AB19

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedPALYNZIQATCA16AB19REGISTER NO.CZ-0238468PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Pegvaliase is registered in 10 of 19 countries.

Countries holding a registration under ATC A16AB19 (pegvaliase), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 6 of them publish a price we can compare per daily dose

Pegvaliase · ATC A16AB19

10 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
PEGVALIASE
Manufacturer
BioMarin International Limited, Dublin
Country
Czechia (CZ)
ATC code
A16AB19
ATC class
Pegvaliase
Defined daily dose
30 mg, P
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

20 interactions on record for pegvaliase.

Graded by severity as the source publishes them — 20 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Pegvaliase · interactions on record

20 records

  • 20 moderate

Most severe, free to view

  • NaloxegolA06AH03moderate
  • Coagulation factor IX, II, VII and X in combinationB02BD01moderate
  • Coagulation factor VIIIB02BD02moderate
  • Coagulation factor IXB02BD04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9543ae25-024e-4689-84c9-8da939ef615a
GET /v1/drugs/9543ae25-024e-4689-84c9-8da939ef615a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "INJ SOL ISP",
  "source": "sukl",
  "strength": "10MG",
  "pack_size": "1X0,5ML",
  "substance": "PEGVALIASE",
  "cz_kod_sukl": "0238468",
  "product_type": "BT",
  "substance_codes": "20557",
  "registration_state": "R",
  "registration_number": "EU/1/19/1362/002"
}

See everything about pegvaliase.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.